Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
SHANGHAI, March 29, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, today announced its financial results for full year ended December 31, 2021, along with a corporate progress update. "Despite a challenging backdrop for the...
ILC Dover Announces Liquid Single-Use Bioprocessing Bags for Rapidly Growing Biotherapeutics and Cell & Gene Therapy Markets
NEWARK, Del., March 29, 2022 /PRNewswire/ -- ILC Dover LP ("ILC Dover" or the "Company"), specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, announced its launch of liquid single-use bioprocessing bags, representing the first of many new products for handling and supply of sterile liquids for the biotherapeutics market. This expansion is a continuation of ILC Dover's solution set...
VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update
Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday March 31, 08.00a.m. Eastern time to discuss its financial and operating results for the full fiscal year 2021, in addition to providing a...
Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%
Financial Highlights of the year ended December 31, 2021: Revenue amounted to RMB2,104.1 million, representing a year-on-year (YoY) increase of 201.9% Gross profit amounted to RMB651.0 million, representing a YoY increase of 113.5% Adjusted Non-IFRS net profit amounted to RMB352.5 million Adjusted earnings per share amounted to HK$0.21 HONGKONG, March 29, 2022 /PRNewswire/ -- On...
Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany
BEIJING, March 28, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as "Biocytogen") announced the opening of the Biocytogen Europe Innovation Center (BEIC) in Heidelberg, Germany. Local government representatives, clinical experts, and colleagues and collaborators from multi-national companies made speeches at the opening ceremony. Dr. Vivian Tian, Head of BEIC, hosted the event, and introduced Biocytogen's...
Clarity’s US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment
SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT05249127) for patients with prostate cancer is open for recruitment. COBRA (Copper-64 SAR-BisPSMA in Biochemically Recurrent prostAte cancer) is a Phase...
First-ever integrated EEG and neurotherapeutics device iSyncWave wins the 2022 Red Dot Design Award
SEOUL, South Korea, March 28, 2022 /PRNewswire/ -- AI-based digital mental healthcare platform company iMediSync has announced that their product "iSyncWave" has won the 2022 Red Dot Design Award for its innovative and creative design as a dry EEG headset. The next generation dry EEG measurement device, iSyncWave Hosted by Germany's Design Zentrum Nordheim Westfalen, the Red...
Tigermed Reports Strong 2021 Full-Year Results
HANGZHOU, China, March 28, 2022 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its annual results for the year ended December 31, 2021 (the "Reporting Period"). This press release is for information...
At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma
Early results showed 2 laBCC (locally advanced Basal Cell Carcinoma) subjects out of 10 experienced a Partial Response (30% decrease in tumor size) at week #24. The first biopsy analysis in the laBCC subject showed a more than 90% decrease of GLI-1 expression at week #8 (GLl-1 is involved...
AXA offers free additional ‘Cleaning and Sanitising Benefit’ to home contents insurance and SME customers
HONG KONG, March 28, 2022 /PRNewswire/ -- In light of the ongoing outbreak of COVID-19, AXA Hong Kong (AXA) takes another step to safeguard our customers. From today until 30 April 2022, AXA's designated home contents insurance and small and medium enterprise (SME) customers are entitled to a free additional 'Cleaning and Sanitising Benefit' to ensure a safe and healthy environment...
